We are live on
!
Find out more
SL
Siren LLC Portfolio holdings
AUM
$3.61B
1-Year Est. Return
203.3%
This Fund
S&P 500
This Quarter
Est. Return
+36.54%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
+$796M
(+31%)
Cap. Flow
+$176M
Cap. Flow
% of AUM
5.24%
Top 10 Holdings %
Top 10 Hldgs %
46.31%
Holding
141
New
26
Increased
29
Reduced
24
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$59.1M |
| 2 |
Olema Pharmaceuticals
OLMA
|
+$58.7M |
| 3 |
Zymeworks
ZYME
|
+$36.6M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$29M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$28.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$57.3M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$56M |
| 3 |
Rezolute
RZLT
|
+$45.8M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$31.6M |
| 5 |
Dyne Therapeutics
DYN
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.02% |
| 2 | Technology | 3.72% |
| 3 | Communication Services | 1.9% |
| 4 | Real Estate | 0.59% |
| 5 | Consumer Discretionary | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$5.96B
| $477M | 14.22% |
10,825,013
+1,575,008
| +17% | +$59.1M |
|
2
Kymera Therapeutics
KYMR
$9.14B
| $256M | 7.63% |
3,286,830
-141,320
| -4% | -$9.54M |
|
|
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
| $152M | 4.53% |
500,000
+7,010
| +1% | +$2.29M |
|
4
Edgewise Therapeutics
EWTX
$4.48B
| $112M | 3.35% |
4,529,990
+632,891
| +16% | +$12.7M |
|
5
Revolution Medicines
RVMD
$40.1B
| $106M | 3.17% |
1,335,075
+291,355
| +28% | +$19.1M |
|
|
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
| $101M | 3% |
4,027,517
+800,000
| +25% | +$20.3M |
|
|
7
Arrowhead Research
ARWR
$12.2B
| $99.6M | 2.97% |
1,500,476
-1,169,404
| -44% | -$57.3M |
|
|
BCAX
8
Bicara Therapeutics
BCAX
$1.88B
| $87.8M | 2.62% |
5,216,969
| – | – |
|
|
9
Olema Pharmaceuticals
OLMA
$1.08B
| $82.5M | 2.46% |
+3,300,700
| New | +$58.7M |
|
10
Disc Medicine
IRON
$2.87B
| $78.5M | 2.34% |
988,401
+75,000
| +8% | +$6.34M |
|
11
Structure Therapeutics
GPCR
$3.53B
| $75M | 2.24% |
1,078,698
+51,887
| +5% | +$2.12M |
|
12
Tango Therapeutics
TNGX
$4.39B
| $72.3M | 2.16% |
8,165,374
+2,282,186
| +39% | +$19.7M |
|
13
Arcus Biosciences
RCUS
$3.58B
| $71.7M | 2.14% |
3,007,077
+95,000
| +3% | +$1.94M |
|
14
Stoke Therapeutics
STOK
$1.84B
| $71.3M | 2.13% |
2,247,347
| – | – |
|
15
Crinetics Pharmaceuticals
CRNX
$8.87B
| $70.2M | 2.09% |
1,507,636
-180,975
| -11% | -$8.06M |
|
|
16
Dyne Therapeutics
DYN
$4.16B
| $68.5M | 2.04% |
3,502,941
-1,226,233
| -26% | -$23.2M |
|
|
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
| $64.8M | 1.93% |
2,578,396
| – | – |
|
18
Cogent Biosciences
COGT
$6.96B
| $57.9M | 1.73% |
1,629,279
-95,000
| -6% | -$2.67M |
|
|
SEPN
19
Septerna Inc
SEPN
$1.5B
| $55.8M | 1.66% |
2,000,000
-202,514
| -9% | -$4.84M |
|
20
Taysha Gene Therapies
TSHA
$1.64B
| $55.7M | 1.66% |
10,129,913
-884,824
| -8% | -$4.3M |
|
21
Rhythm Pharmaceuticals
RYTM
$7.38B
| $53.5M | 1.6% |
499,975
| – | – |
|
22
Ascendis Pharma A/S
ASND
$16.7B
| $50.3M | 1.5% |
235,862
| – | – |
|
|
RAPT
23
DELISTED
RAPT Therapeutics
RAPT
| $46.6M | 1.39% |
1,375,000
+794,534
| +137% | +$24.7M |
|
24
Taboola.com
TBLA
$1.36B
| $46M | 1.37% |
9,969,495
| – | – |
|
25
Lexicon Pharmaceuticals
LXRX
$1.02B
| $44.8M | 1.34% |
38,918,903
| – | – |
|
Similar funds
U
WB
SPC
SCM
ACM
GCM
VI
JFG
Siren LLC's Q4 2025 Portfolio in Review
As of Q4 2025, Siren LLC held 141 positions worth $3.35B, up 31% from $2.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Siren LLC deployed $176M of net new capital in Q4 2025, opening 26 new positions and adding to 29 existing holdings. Its largest new stake was Olema Pharmaceuticals: 3,300,700 shares worth $82.5M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Arrowhead Research, an estimated $57.3M trimmed.
- Siren LLC's largest Q4 2025 buy was Olema Pharmaceuticals: 3,300,700 shares worth $82.5M.
- Siren LLC added most to Scholar Rock in Q4 2025, an estimated $59.1M increase.
- Siren LLC's biggest Q4 2025 reduction was Arrowhead Research, cutting an estimated $57.3M.
- Siren LLC fully exited Avidity Biosciences in Q4 2025, selling an estimated $56M.
- Siren LLC's ten largest holdings make up 46% of its $3.35B portfolio in Q4 2025.
- Siren LLC opened 26 new positions and closed 28 in Q4 2025.
- Siren LLC's portfolio value rose 31% quarter-over-quarter to $3.35B.
Based on Siren LLC's 13F filing for Q4 2025, filed 13 Feb 2026.